VANCOUVER, BC and SEOUL, South Korea, March 14,
2023 /CNW/ - ("NexOptic") (TSXV: NXO) (OTCQB:
NXOPF) (FSE: E3O1) and ("IntroMedic") jointly announce that
they have entered a non-binding memorandum of understanding
("MOU"). IntroMedic is a leading innovator in global capsule
endoscopy technology and medical imaging analysis whose
objective is to always improve the quality of its
patented imaging and analysis medical offerings. Further
detail can be found on IntroMedic's website: IntroMedic
"In our ongoing efforts to always put patients and medical
experts first, I am very encouraged by the measurable improvements
to image quality that NexOptic has been able to demonstrate to us."
Said Mr. Andrew Shim, President of
IntroMedic.
Capsule endoscopy is a procedure that uses a tiny wireless
camera to take pictures of the digestive tract. IntroMedic's
capsule endoscopy camera sits inside a vitamin-size capsule that is
swallowed. As the capsule travels through the digestive tract, the
camera takes thousands of pictures that are transmitted to a
recorder worn on a belt around the patients' waist. Growing in
popularity, capsule endoscopy is far less invasive and more
comfortable to the patient than more traditional endoscopy
procedures.
Specifically, IntroMedic's MiroCam® capsule endoscope
offers a broader field of view of 170 degrees which enables a more
thorough diagnosis of parts of the digestive system, further its
12-hour operational time mitigates many concerns common in
competitive offerings. Together with IntroMedic's patented Human
Body Communication technology (HBC), its Augmented Live-body Image
Colour-Spectrum Enhancement (ALICE) and its Medical Image
Processing technology (MIP), MiroCam® delivers many
technological advantages when compared to its
competitors.
NexOptic and IntroMedic initiated dialogue late in 2021 and have
undergone several stages of evaluation and development since.
Paul McKenzie, CEO of NexOptic
stated, "It's been an encouraging relationship with IntroMedic and
we are excited for the possibility of playing a role in more
technologies that further benefit human health and lifestyle."
Today's announcement demonstrates both companies' positive
outlook on executing a potential per capsule, licence model. If
successful, this would mark the second commercial deployment of
ALIIS™ into medical imaging devices, a field that NexOptic is
well-positioned to rapidly expand into due to demanding use-cases
that are frequently dependant on small lens factors.
What You Need to Know About
NexOptic
NexOptic is an innovative imaging AI company headquartered in
Vancouver, Canada with operations
in Seoul, South Korea, offering
world-leading patented and patent pending AI solutions for imaging
known as ALIIS™ (All Light Intelligent Imaging Solutions). NexOptic
simultaneously influences the imaging and AI industries and is a
Preferred Partner in the NVIDIA Partner Network, a member of the
Arm® AI Partner Program, and a member of the
Qualcomm® Platform Solutions Ecosystem.
For more information, visit www.nexoptic.com
Forward-Looking
Statements
This news release contains forward-looking statements and
forward-looking information (together, "forward-looking
statements") within the meaning of applicable securities laws. All
statements, other than statements of historical facts, are
forward-looking statements. Generally, forward-looking statements
can be identified by the use of terminology such as "plans,"
"expects," "estimates," "intends," "anticipates," "believes" or
variations of such words, or statements that certain actions,
events or results "may," "could," "would," "might," "will be
taken," "occur," or "be achieved." Forward-looking statements in
this news release include, without limitation, the Company's
expectations concerning the size of the Financing, its ability to
close the Financing in whole or in part or at all and its plan for
the proceeds of the Financing. Forward-looking statements involve
risks, uncertainties and other factors disclosed under the heading
"Risk Factors" and elsewhere in NexOptic's filings with Canadian
securities regulators, that could cause actual results,
performance, prospects and opportunities to differ materially from
those expressed or implied by such forward-looking statements.
Although NexOptic believes that the assumptions and factors used in
preparing these forward-looking statements are reasonable based
upon the information currently available to management as of the
date hereof, actual results and developments may differ materially
from those contemplated by these statements. Readers are therefore
cautioned not to place undue reliance on these statements, which
only apply as of the date of this news release, and no assurance
can be given that such events will occur in the disclosed times
frames or at all. Except where required by applicable law, the
Company disclaims any intention or obligation to update or revise
any forward-looking statement, whether because of new information,
future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this news release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nexoptic-technology-corp-signs-mou-with-intromedic-a-global-capsule-endoscopic-imaging-corporation-301771252.html
SOURCE NexOptic Technology Corp.